Breast Augmentation (Implants) | Additional implant consent and surveillance questions

Breast augmentation involves choosing implant type, size, placement and incision based on your tissues and goals. Implants may be saline or silicone gel, placed behind breast tissue or muscle, with incision around the areola, fold or armpit depending on breast characteristics and preferences. Implant size and shape are chosen with your tissue dimensions and goals in mind. Manufacturer information and consent forms are part of informed consent, alongside discussion of alternatives, risks and realistic expectations. A complete discussion also covers possible need for further surgery. Reading them helps you understand implant-specific details, but your surgeon still individualizes decisions because tissue limitations and healing vary. You should not feel rushed; ask questions until you understand.

These documents identify the exact device if you need future surgery, imaging or warranty support. The package insert and warranty information describe device-specific details, while manufacturer links provide current rupture and capsular contracture data. Your surgeon should also discuss long-term revision, rupture and complication data so you can compare realistic risks. The discharge letter should include diagnosis, procedure, implant passport, postoperative care and follow-up program; keeping these together helps future doctors understand your device and plan. Manufacturer links can be reviewed again at home. This is not a guarantee of device lifespan. Keeping copies protects you if records are lost or you move, and supports continuity of care.

Textured shells were developed to disrupt parallel collagen alignment and reduce capsular contracture; meta-analyses in primary cosmetic augmentation have reported lower contracture rates with textured implants. Smooth implants may have higher capsular contracture risk because collagen fibers align parallel to the surface. Textured surfaces can enhance immune response and bacterial biofilm formation, increasing infection risk. Textured implants offer more pocket stability and may reduce lower-pole stretch, but they wrinkle more easily and can cause waterfall deformity under very lax skin. Textured devices also carry concerns about double capsule, late seroma and BIA-ALCL. Comparative evidence is heterogeneous and context-dependent. The trade-off is accepting possible sequelae for stability or contracture benefit. Implant choice should be tissue-based and discussed openly during consent.

Late seroma is fluid collection at least one year after surgery, distinct from early postoperative seroma. Its exact mechanism and risk factors are unknown. Proposed causes include vascular or lymphatic leakage with inflammation, bacterial infection, hematoma, trauma, or idiopathic factors related to augmentation or reconstructive surgery, cancer, or lymphoproliferative disease. Any suspicious mass after normal healing should be evaluated like any other breast lump. MRI may be indicated after long-term implantation, but no absolute recommendation exists for timing or exchange; modern implants will probably stay intact for ten or even twenty or more years. It is reasonable to obtain the opinion of the original plastic surgeon.

Most reported cases present with similar symptoms, especially swelling from a fluid collection; a mass from the capsule wall, axillary lymph node enlargement and, less commonly, widespread disease with B symptoms may occur. Because a delayed seroma can be associated with BIA-ALCL or other malignancies in about 10% of cases, it warrants immediate clinical assessment. Evaluation may include ultrasound first, MRI if results are unclear, plus fluid or tissue sampling and pathology review. Textured implants deserve particular attention, and NCCN guidance supports imaging before any capsulectomy for implant-related symptoms. Prompt specialist review helps distinguish benign seroma from malignancy without unnecessary alarm.

FDA guidance recommends initial implant screening for rupture between five and six years after surgery, then every two to three years. MRI is considered the gold standard, but cost may limit access, so ultrasound or mammography may be alternatives. ASPS notes routine screenings can verify an implant is intact and detect rupture or silicone leakage, even without symptoms. For cancer screening, ACS recommends annual mammograms starting at age forty-five for average-risk women, with the option to begin at forty; women with implants generally follow the same schedule, but Eklund displacement views are used because implants can obscure breast tissue. Most women need the same follow-up and mammogram screening as women without prior surgery.

FDA-approved breast implants undergo extensive testing, and most people with implants have no serious complications. Still, some patients attribute fatigue, “brain fog,” muscle or joint pain and rash to breast implant illness. The cause is poorly understood; possible mechanisms under investigation include immune responses to bacterial biofilms, allergy to implant components, patient immune hyperreactivity, or a somatoform disorder. A 1999 Institute of Medicine review found insufficient evidence to implicate silicone implants in systemic illness, and symptoms also occur in women who never had implants. Most affected patients do not have scleroderma or lupus; some have fibromyalgia or soft-tissue rheumatism, and some symptoms respond to local steroid injections.

Removal may be considered for implant problems, breast changes or a change of mind, and more than one reason can be behind your choice. If capsular contracture, significant rupture or another capsule problem is found, capsulectomy may be needed. If breast tissue is lax or sagging after removal, after replacement with a smaller implant, or if shape was a reason for removal, a mastopexy may be performed. You may also choose replacement or fat transfer instead of an implant. Some implants do not last quite so long, while others last many years longer without problems. Breast augmentation is major surgery with potential risks, and the result you may hope for cannot be guaranteed.

A capsule is scar tissue that naturally forms around an implant. Removal is warranted if it is calcified, contains a mass, or has silicone embedded in it; capsular contracture or significant rupture can also make capsulectomy necessary. When the goal is simply downsizing or improving breast shape, capsule removal is not generally required; retaining it can provide structure for overlying breast flaps and optimize blood supply for the nipple-areola complex and mastopexy. The decision depends on the indication and surgical plan, not routine removal. Capsulectomy is not automatic; it is chosen based on clinical findings and surgical goals. Dr. Purohit can discuss benefits, limitations and likely outcomes during consultation.

Breasts change with ageing, weight fluctuations, hormonal factors and gravity. Pregnancy and breastfeeding can enlarge then shrink breasts, reducing skin elasticity and causing relaxation; implants may partly reduce this effect. Younger patients with stable weight and appropriately sized implants may have lower risk of aesthetic disturbance over ten years; after 35 or after pregnancies, ptosis risk rises, especially with implants over 250 g. Implants are not lifetime devices and may need replacement. Later decisions depend on degree of ptosis, tissue quality, implant condition and preferences; options may include lift, exchange or observation. Individual assessment is essential. Revision timing depends on your goals and health.

Implants may need imaging as they age to detect rupture or palpable concerns, and you should tell your mammography technologist about implants because additional views may be necessary. One FDA recommendation is MRI three years after surgery and every two years after that; another FDA recommendation is MRI or ultrasound five to six years after silicone implant placement and every two to three years thereafter. These recommendations may change. Additional surgery to the breasts or implant is likely over your lifetime; implants are not considered lifetime devices and removal, with or without replacement, is likely. Capsular contracture, if severe, may require surgery.

FDA guidance cited here recommends MRI or high-resolution ultrasound screening for silicone implant rupture six years after placement and every two to three years thereafter. Surveillance can increase detection of asymptomatic rupture, which may allow planned removal before silicone migration. Symptomatic rupture may show breast size, shape or texture changes, pain, palpable lumps, or capsular contracture. A recalled device alone does not mean you need surgery; assessment depends on implant type, symptoms, imaging and your preferences. with your surgeon's review and overall health before any decision. Silicone migration can occur from intact or ruptured implants, although symptomatic migration is exceedingly rare in newer-generation implants. Confirmatory imaging remains appropriate when symptoms raise concern.